Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)

Keros Therapeutics filings provide 7 years of Equity Ratio readings, the most recent being 0.9 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 3.37% to 0.9 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.9, a 3.37% decrease, with the full-year FY2025 number at 0.9, down 3.37% from a year prior.
  • Equity Ratio hit 0.9 in Q4 2025 for Keros Therapeutics, down from 0.95 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2021 to a low of 0.9 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.93 (2022), compared with a mean of 0.93.
  • Biggest five-year swings in Equity Ratio: soared 334.82% in 2021 and later decreased 5.08% in 2022.
  • Keros Therapeutics' Equity Ratio stood at 0.95 in 2021, then fell by 5.08% to 0.9 in 2022, then dropped by 0.72% to 0.9 in 2023, then increased by 3.36% to 0.93 in 2024, then fell by 3.37% to 0.9 in 2025.
  • The last three reported values for Equity Ratio were 0.9 (Q4 2025), 0.95 (Q3 2025), and 0.93 (Q2 2025) per Business Quant data.